215 related articles for article (PubMed ID: 30157904)
1. The inclusion of real world evidence in clinical development planning.
Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Methods for the inclusion of real-world evidence in network meta-analysis.
Jenkins DA; Hussein H; Martina R; Dequen-O'Byrne P; Abrams KR; Bujkiewicz S
BMC Med Res Methodol; 2021 Oct; 21(1):207. PubMed ID: 34627166
[TBL] [Abstract][Full Text] [Related]
4. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
5. Seamlessly expanding a randomized phase II trial to phase III.
Inoue LY; Thall PF; Berry DA
Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
[TBL] [Abstract][Full Text] [Related]
6. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
Friede T; Häring DA; Schmidli H
Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
[TBL] [Abstract][Full Text] [Related]
7. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
[TBL] [Abstract][Full Text] [Related]
8. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
9. Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA
Cook JA; Julious SA; Sones W; Hampson LV; Hewitt C; Berlin JA; Ashby D; Emsley R; Fergusson DA; Walters SJ; Wilson EC; MacLennan G; Stallard N; Rothwell JC; Bland M; Brown L; Ramsay CR; Cook A; Armstrong D; Altman D; Vale LD
Health Technol Assess; 2019 Oct; 23(60):1-88. PubMed ID: 31661431
[TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
11. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
14. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
16. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
Chataway J; Nicholas R; Todd S; Miller DH; Parsons N; Valdés-Márquez E; Stallard N; Friede T
Mult Scler; 2011 Jan; 17(1):81-8. PubMed ID: 20798135
[TBL] [Abstract][Full Text] [Related]
17. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
18. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
Chang M; Wang J
J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
[TBL] [Abstract][Full Text] [Related]
19. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
20. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.
Cook JA; Hislop J; Adewuyi TE; Harrild K; Altman DG; Ramsay CR; Fraser C; Buckley B; Fayers P; Harvey I; Briggs AH; Norrie JD; Fergusson D; Ford I; Vale LD
Health Technol Assess; 2014 May; 18(28):v-vi, 1-175. PubMed ID: 24806703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
